Diagnosis and therapy of superficial bladder cancer;Diagnostika a terapie povrchových nádorů močového měchýře

Casopis Lekaru Ceskych

Volumn 141, Issue 23, 2002, Pages 723-728

  Babjuk, M ^a   Dvoracek J ^a  

^a NONE

Author keywords

Intravesical BCG immunotherapy; Intravesical chemotherapy; Superficial bladder transitional cell carcinoma

Indexed keywords

BCG VACCINE; DOXORUBICIN; INTERFERON; MITOMYCIN C;

BIOPSY; BLADDER CARCINOMA; BLADDER TUMOR; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CYSTOSCOPY; DRUG INDUCED DISEASE; GENERAL ANESTHESIA; HISTOPATHOLOGY; HUMAN; PAPILLOMA; PROGNOSIS; REVIEW; SPINAL ANESTHESIA; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 85032069223     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Ústav zdravotnických informací a statistiky České republiky, 2000.
2. Tumors of the bladder. In: Tanagho, E. A., McAninch, J W., eds: Smith's General Urology. 12th Ed., Lange Medical Publications 1988, s. 355-360.
3. Jewett, H. J., Strong, G. H.: Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J. Urol., 55. 1946. s. 366-372.
4. Ondruš, D. et al.: Nádory močového mechúra. Osveta, Martin 2000, s. 256.
5. Holmang, S., Hedelin, H., Anderström, C. et al.: The importance of the depths of invasion in stage TI bladder carcinoma: a prospective cohort study. J. Urol., 157, 1997, s. 800-804.
6. Hermann, G., Horn, T., Steven, K.: The influence of the level of lamina propria invasion and the prevalence of P53 nuclear accumulation on survival in stage Tl transitional cell bladder cancer. J. Urol., 159, 1998, s. 91-94.
7. Lamm, D. L.: Carcinoma in situ. Urol. Clin. North. Am., 19, 1992, s. 499-508.
8. Hudson, M. A., Herr, H. W.: Carcinorna in situ of the bladder. J. Urol., 153, 1995, s. 564-572.
9. Riddle, P. R., Chisholm, G. D., Trott, P. A., Pugh, R. C. B.: Flat carcinoma in situ of the bladder. Br. J. Urol., 47, 1975, s. 829-833.
10. Kurth, K. H., Bouffioux, C., Sylvester, R. et al.: Treatment of superficial bladder tumors: achievements and needs. Eur. Urol., 37, 2000 (Suppl 3). s. 1-9.
11. Brausi, M., Kurth, K.-H., van der Meijden, A. P. et al.: Variability in the three months recurrenee rate after TUR in superficial transitional carcinoma of the bladder: a combined analysis of 8 EORTC studies. J. Urol., 159, 1998 (Suppl.), s. 143.
12. Klän, R., Loy, V., Huland, H.: Residual tumor discovered in routine second transurethral resection in patients with stage Tl transitional cell carcinoma of the bladder. J. Urol., 146, 1991, s. 316-318.
13. Herr, H. W.: The value of a second transurethral resection in evaluating patients with bladder tumors. J. Urol., 162, 1999, s. 74-76.
14. Vögeli, T. A., Grimm, M.-O., Ackermann, R.: Prospective study for quality control of TUR of bladder tumors by routine 2nd TUR (reTUR). J. Urol., 159, 1998 (Suppl.), s. 143.
15. Babjuk, M., Petřík, R., Jirsa, M.: Fluorescenční diagnostika nádorů močového měchýře. Triton, Praha 2001, 126 s.
16. Kriegmair, M. Baumgartner, R., Knüchel, R. et al.: Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J. Urol., 155. 1996. s. 105-110.
17. König, F., McGovern, F. J., Larne, R. et al.: Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaelvulinic acid. Br. J. Urol. Int., 83, 1999, s. 129-135.
18. Riedl, C. R., Daniltchenko, D., König, F. et al.: Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J. Urol., 165, 2001, s. 1121-1123.
19. Kurth, K. H., Denis, L., Bouffioux, Ch. et al.: Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer. 31A, 1995, s. 1840-1846.
20. Holmang, S., Hedelin, H., Anderström, C., Holmberg, E. et al.: Recurrence and progression in low grade papillary urothelial tumors. J. Urol., 162, 1999, s. 702-707.
21. Leblanc, B., Duclos, A. J., Benard, F. et al.: Long-term follow-up of initial Ta grade I transitional cell carcinoma of the bladder. J. Urol., 162, 1999, s. 1946-1950.
22. Herr, H. W.: Tumour progression and survival in patients with TIG3 bladder tumours: 15-year outcome. Br. J. Urol., 80, 1997, s. 762-765.
23. Jones, H. C., Swinney, J.: Thiotepa in the treatment of tumours of the bladder. Lancet, 2, 1961, s. 615-618.
24. Bouffioux, Ch., Denis, L., Oosterlinck, E. et al.: Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European organization for research and treatment of cancer randomized trial comparing in travesical in stillation of thiotepa, doxorubicin and cisplatin. J. Urol., 148, 1992, s. 297-301.
25. Flanigan, R. C., Ellison, M. F., Butler, K. M., Gomella, L. G.: A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers. J. Urol., 136, 1986, s. 35-37.
26. Bouffioux, Ch., Kurth, K. H., Bono, A. et al.: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and hort-term versus long-term treatment. J. Urol., 153, 1995, s. 934-941.
27. Oosterlinck, W., Kurth, K. H., Schröder, F. et al.: A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, Tl papillary carcinoma of the bladder. J. Urol., 149, 1993, s. 749 až 752.
28. Lamm, D. L., Riggs, D. L., Traynelis, Ch. L., Nseyo, U.: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol., 153, 1995, s. 1444-1450.
29. Pawinski, A., Sylvester, R., Kurth, K. H. et al.: A combined analysis of European organisation for research and treatment of cancer, and Medical research council randomised clinical trials for the prophylactic treatment of stage TaTl bladder cancer. J. Urol., 156, 1996, s. 1934 až 1941.
30. Morales, A., Eidinger, D., Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116, 1976, s. 180-182.
31. Jackson, A. M., Ivshina, A. V., Senko, O. et al.: Prognosis of intravesical bacillus Calmette-Guerin therapy aften superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J. Urol., 159, 1998, s. 1054-1063.
32. Lamm, D. L., Blumenstein, B. A., Crissman, J. D. et al.: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta Tl and carcinoma in situ transitional cell carcinoma of the bladder: a randomised southwest oncology group study. J. Urol., 163, 2000, s. 1124-1129.
33. Lamm, D. L., Reichert, D. F., Harris, S. C., Lucio, R. M.: Immunotherapy of murine transitional cell carcinoma. J. Urol., 128, 1982, s. 1104-1108.
34. Losa, A., Hurle, R., Lembo, A.: Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J. Urol., 163, 2000, s. 68-72.
35. Mack, D., Höltl, W., Bassi, P. et al.: The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J. Urol., 165, 2001, s. 401-403.
36. Lamm, D. L., van der Meijden, A. P. M., Morales, A. et al.: Incidence and treatrnent of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol., 147. 1992, s. 596-600.
37. Bohle, A., Balek, F., von Wietersheim, J., Jocham, D.: The quality of life during intravesieal bacillus Calmette-Guerin therapy. J. Urol., 155, 1996, s. 1221-1226.
38. Pacik, D., Vit, V., Turjanica, M.: Úskalí intravezikální imunoterapie povrchového karcinomu močového měchýře BCG vakcínou. Rozhl. Chir., 76, 1997, s. 3-5.
39. Kurth, S. H., Schellhammer, P. F., Okajima, E. et al.: Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra: global strategy for bladder cancer. Int. J. Urol., 2, 1995 (Suppl. 2), s. 8-22.
40. Lamm, D. L.: BCG in perspective: Advances in the treatment of superficial bladder cancer. Eur. Urol., 27, 1995 (Suppl. 1), s. 2-8.
41. Lamm, D. L., Blumenstein, B. A., Crawford, E. D. et al.: A randomised trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med., 325. 1991, s. 1205-1209.
42. Lundholm, C., Norlen, B. J., Ekman, P. et al.: A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol., 156, 1996, s. 372-376.
43. van der Meijden, A. P. M., Brausi, M., Zambon, V. et al.: Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Tare Tl papillary carcinoma of the bladder: a European organization for research and treatment of cancer genito-urinary group randomized phase III trial. J. Urol., 166, 2001, s. 476-481.
44. Herr, H. W.: Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J. Urol., 163, 2000, s. 60-62.
45. Belldegrun, A., Franklin, J. R., O'Donell, M. A. et al.: Superficial bladder cancer: the role of interferon-α. J. Urol., 159, 1998, s. 1793 až 1801.
46. Kälble, T., Beer, M., Mendoza, E. et al.: BCG vs. Interferon A zur Rezidivprophylaxe beim oberflächlichen Harnbalsenkarzinom. Urologe A, 33, 1994, s. 133-137.
47. Jurincic-Winkler, C. D., Metz, K. A., Beuth, J., Klippel, K. F.: Kyehole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur. Urol., 37, 2000 (Suppl. 3), s. 45-49.
48. Nseyo, U. O., Shumaker, B., Klein, E. A., Sutherland, K.: Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J. Urol., 160, 1998, s. 39-44.
49. Kriegmair, M., Baumartner, R., Lumper, W. et al.: Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br. J. Urol., 77, 1996, s. 667-671.
50. Stöckle, M., Alken, P., Engelmann, U. et al.: Radikale Zystektomie - Oft zu spät? Akt. Urol., 17, 1986, s. 234-239.